Nov. 16 at 2:50 PM
The odds are
$DAWN shareholders will lose. It used to be considered wisdom for a smaller cap bio to sell after FDA approval. Everyone wins, including healthcare costs via consolidation. DAWN beat the considerable odds with Ojemda & is chancing the value created for shareholders on DAY-301 &
$MRSN in spite of the odds. Last year @ JP Morgan, DAWN's CEO appeared to almost boast about building a business with such high failure rates.
$PBYI & countless others tried the same after Nerlynx's approval back in 2017. PBYI shareholders are down 95% since.
$GERN shareholders are off 80% since Rytelo's approval. Perhaps the MDS read 2.5 years later will pay off?
$IMCR we wait as well
Attached are screenshots from government, industry & academia around the odds of scoring a cancer drug approval
Having lost a loved one in her early 50s to ovarian cancer 2 years ago, this is not to bash the virtue of cancer research. Consolidation should be encouraged. Odds or scale?
Just 1 opinion
